 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | LHP588 / Lighthouse Pharma
New P2 trial: Study of LHP588 in Subjects with P. Gingivalis-Positive Alzheimer's Disease (clinicaltrials.gov) - Feb 26, 2025
P2, N=300, Recruiting, Sponsor: Lighthouse Pharmaceuticals, Inc.
- LHP588 / Lighthouse Pharma
Phase 2 Study Design and New Data from the Phase 1 SAD/MAD Trial of LHP588, A Second-Generation Gingipain Inhibitor for the Treatment of P. Gingivalis - Positive Alzheimer Dementia (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_2469;
Conclusion : LHP588 was well-tolerated in healthy volunteers without evidence of hepatic safety signals to date, and its PK profile was supportive of once daily dosing. The Phase 2 trial of LHP588 proposed to start in late 2023 will be similar in design to the prior atuzaginstat study but will be restricted to subjects with Pg + saliva.
- ||| LHP588 / Lighthouse Pharma
Trial completion: A Single and Multiple Ascending Dose Study of COR588 (clinicaltrials.gov) - Jul 20, 2022
P1, N=64, Completed, Sponsor: Cortexyme Inc.
The Phase 2 trial of LHP588 proposed to start in late 2023 will be similar in design to the prior atuzaginstat study but will be restricted to subjects with Pg + saliva. Recruiting --> Completed
- | atuzaginstat (COR388) / Cortexyme, COR588 / Cortexyme
Preclinical, Journal: Increased levels of phospho-tau217 in neuron cultures and CVN mice infected with Porphyromonas gingivalis. (Pubmed Central) - Feb 4, 2022
In vitro this was apparent at low infection levels that might reflect the physiological level of gingipain exposure. Phospho-tau217 is emerging as a specific biomarker for AD and these results further validate P. gingivalis-infected neuron cultures and mice as models for AD.
- ||| LHP588 / Lighthouse Pharma
Enrollment open: A Single and Multiple Ascending Dose Study of COR588 (clinicaltrials.gov) - Sep 10, 2021
P1, N=64, Recruiting, Sponsor: Cortexyme Inc.
Phospho-tau217 is emerging as a specific biomarker for AD and these results further validate P. gingivalis-infected neuron cultures and mice as models for AD. Not yet recruiting --> Recruiting
- ||| LHP588 / Lighthouse Pharma
New P1 trial: A Single and Multiple Ascending Dose Study of COR588 (clinicaltrials.gov) - Jun 10, 2021
P1, N=88, Not yet recruiting, Sponsor: Cortexyme Inc.